Senior Biotech Leaders

Press Release


For more information:
Rebecca Stauffer
AAPS Communications Manager
[email protected]

Senior Biotech Leaders to Discuss Cell and Gene Therapy Market

Exclusive Session Explores Global Market Access, Development Speed, Among Other Points

Arlington, VA—Biotech executives are encouraged to register for and attend the exclusive executive track session, “Cell and Gene Therapies at the Intersection of Business and Science,” scheduled for May 14 at 9:30 a.m. during the AAPS National Biotechnology Conference (NBC) in San Francisco.

Potens Pharmaceuticals Founder Praveen Tyle, Ph.D., will moderate a panel focused on the current state of cell and gene therapies. The discussion will center on practical insights into how biotech leaders are addressing market pain points, e.g., global market access, development speed, and organizational capabilities. Other discussion points include business considerations and their intersection with scientific advancement, and how demand for these advanced therapeutics impacts global health.

“Cell and gene therapies represent the future of biotherapeutic drug development,” said Dr. Tyle, who is also Vice Chair of AAPS’s Business and Partner Development Committee. “Overcoming current challenges to ensure continued growth of these products requires science’s business leaders to come together and work collaboratively across the industry. I’m honored to facilitate this discussion at the NBC.”

According to Vantage Market Research, the global cell and gene therapy manufacturing market should maintain an annual growth rate of 18.2% through the rest of the decade, ultimately, attaining a value of $15.4 billion by 2030 when compared to the current market of $4.7 billion.

“With 30 cell and gene therapy products currently approved for the U.S. market and more in the pipeline, analysts forecast significant growth in this market,” said AAPS Executive Director Tina Morris, Ph.D. “It is important senior biotech leaders understand what is needed to ensure market entry for these products.”

Jason Bock, Ph.D., Co-Founder and CEO of the Cell Therapy Manufacturing Center (CTMC), Nianwei Lin, Ph.D., Co-Founder and President at iXCells Biotechnologies, and Kimberley Buytaert-Hoefen, Ph.D., Executive Director and Global Head of Regulatory Services at QPS, are confirmed to speak in this session.

The NBC takes place May 13-16 at the Hilton San Francsico Union Square. To learn more and to register, visit


American Association of Pharmaceutical Scientists (AAPS) is a 501(c)(3) non-profit association of more than 7,000 scientists and professionals employed in academia, industry, regulatory, and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and various events in person and online.

The AAPS National Biotechnology Conference (NBC) uncovers the latest science and trends that impact today’s research and pharmaceutical markets, specifically in the areas of biologics, biotechnology products, and advanced therapies.